Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Myers

Nurse Practitioner, Psychiatric/Mental Health Sullivan, IN Nurse Practitioner

NPI 1902278476 CMS profile 10582810

2200 N Section St, Sullivan, IN 47882

Open in the dashboard

General payments

$8,034

427 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Myers of Sullivan, IN is reported in the CMS Open Payments database as having received $8,034 across 427 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $897 38
2024 General $659 18
2023 General $2,451 117
2022 General $2,320 129
2021 General $1,707 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Myers
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Jessica Myers were reported at $897. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Jessica Myers Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,707 $166 $54–$482 $132
2022 $2,320 $195 $66–$559 $149
2023 $2,451 $233 $82–$673 $160
2024 $659 $236 $84–$688 $164
2025 $897 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,268 125 payments
  2. Harmony Biosciences LLC $856 30 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $814 32 payments
  4. AstraZeneca Pharmaceuticals LP $728 26 payments
  5. Jazz Pharmaceuticals Inc. $641 23 payments
  6. Electromed, Inc. $529 34 payments
  7. Genzyme Corporation $392 16 payments
  8. Grifols USA, LLC $279 19 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $245 13 payments
  10. Janssen Pharmaceuticals, Inc $243 18 payments
  11. Other $2,038 91 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,630 421 payments
  2. Education $404 6 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $852 91 payments
  2. BREZTRI $572 16 payments
  3. OFEV $570 23 payments
  4. SMARTVEST $529 34 payments
  5. XYWAV $458 16 payments
  6. DUPIXENT $392 16 payments
  7. WAKIX Sleep Medicine $313 10 payments
  8. Prolastin-C Liquid $279 19 payments
  9. Wakix Neurological Disorders $248 14 payments
  10. NUCALA $238 27 payments
  11. Other $4,577 191 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

896

Median for Nurse Practitioner: 389

Drug cost

$413,320

Median for Nurse Practitioner: $21,885

Branded share of claims

67.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prolastin C Alpha-1-Proteinase Inhibitor Brand 11 $145,533
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 157 $120,175
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 51 $42,902
Dupixent Pen Dupilumab Brand 11 $40,999
Caplyta Lumateperone Tosylate Brand 11 $17,911
Breo Ellipta Fluticasone/Vilanterol Brand 32 $14,875
Spiriva Respimat Tiotropium Bromide Brand 16 $10,383
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 13 $6,000
Albuterol Sulfate Hfa Albuterol Sulfate Brand 217 $5,172
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 16 $1,761

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$9,328

Medicare's payments for the services billed

Medicare patients

69

Average age 70

Services billed

127

35 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 64%
Arthritis 59%
Ischemic heart disease 49%
Diabetes 46%
Chronic kidney disease 42%
Heart failure 30%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $222
$222 — —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $111
$111 — —
VRAYLAR
  • AbbVie, Inc. $66
$66 — —
CAPLYTA
  • ITI, Inc. $66
$66 11 —
FANAPT
  • Vanda Pharmaceuticals Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

427 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record